8/13/18 1 Polypharmacy in the Geriatric Client Susan K. Chrostowski, DNP, APRN, ANP-C Objectives › Review changes in the geriatric population affecting future nurse practitioner practice › Discuss pharmacokinetic/pharmacodynamic considerations in the geriatric client. › Explain treatment modifications that need to be implemented for chronic conditions and pharmacology management with the geriatric client. Disclosures › There is no commercial support associated with this educational activity. › The speaker has participated in the past on advisory boards and Speaker’s Bureaus for AbbVie, Bristol-Myers- Squibb, and Pfizer, but currently has no financial relationships with these agencies. › The use of any trade names is solely for familiarity of the audience. What is Polypharmacy? › Numerical › Descriptive › Time span › Healthcare setting (Masnoon, Shakib, Kalisch-Ellett, & Caughey, 2017) Associated Terms › ADE – Adverse drug event › ADR – Adverse drug reaction › MRH – Medication-related harm › MRM – Medication risk mitigation › PIM – potentially inappropriate medication Significance of Polypharmacy
10
Embed
Polypharmacy in the Geriatric Client8/13/18 1 Polypharmacy in the Geriatric Client Susan K. Chrostowski, DNP, APRN, ANP-C Objectives ›Review changes in the geriatric population affecting
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
8/13/18
1
Polypharmacy in theGeriatric ClientSusan K. Chrostowski, DNP, APRN, ANP-C
Objectives
› Review changes in the geriatric population affecting future nurse practitioner practice
› Discuss pharmacokinetic/pharmacodynamic considerations in the geriatric client.
› Explain treatment modifications that need to be implemented for chronic conditions and pharmacology management with the geriatric client.
Disclosures
› There is no commercial support associated with this educational activity.
› The speaker has participated in the past on advisory boards and Speaker’s Bureaus for AbbVie, Bristol-Myers-Squibb, and Pfizer, but currently has no financial relationships with these agencies.
› The use of any trade names is solely for familiarity of the audience.
› 450,000 emergency room visits each year› Older adults are 7 times more likely to be hospitalized› Leading cause of nonsurgical adverse event in hospitals
– Increased length of stay– Higher costs– Increased risk of in-hospital death
› Up to 140,000 deaths annually in U.S.
(Agency for Healthcare Research and Quality [AHRQ], 2018; Centers for Disease Control and Prevention [CDC], 2018; Zhou & Rupa, 2018)
Patient Example27 Potential
Drug Interactions!
8/13/18
4
ADEs Reported to FDA
(U.S. Department of Health and Human Services [DHHS], 2018)
Main Drugs Associated with Adverse Drug Events› Antibiotics and anti-infectives› Antineoplastic drugs, antiallergy and antiemetic drugs› Steroids, insulin and hypoglycemic agents› Anticoagulants› Antidepressants, antipsychotics, benzodiazepines› Cardiovascular drugs – Digoxin, anti-adrenergics› Water, mineral, and uric acid metabolism drugs› Anticonvulsants and anti-Parkinson drugs
(Agency for Healthcare Research and Quality [AHRQ], 2018)
Factors Contributing to Polypharmacy
Increasing Life Expectancy
0
10
20
30
40
50
60
70
80
90
1900 1950 2000 2015
US Trends in Life Expectancy 1900-2015
Male Female Both Sexes
(National Center for Health Statistics. Health, United States, 2016: With chartbook on long-term trends
in health, p. 116)
Multimorbidityv68% have 2 or
more chronic conditions
vNon-chronic conditionsvCancervInjuriesvSurgeryvPneumonia Source: Chronic Disease Management, Essentials of Clinical Geriatrics, 8e
Citation: Kane RL, Ouslander JG, Resnick B, Malone ML. Essentials of Clinical Geriatrics, 8e; 2017 Available at: http://accessmedicine.mhmedical.com/content.aspx?bookid=2300§ionid=178119282 Accessed: March 24, 2018
› Hypertension:– “Many patients can be started on a single agent, but
consideration should be given to starting with 2 drugs of different classes for those with stage 2 hypertension . . .
– Many patients started on a single agent will subsequently require ≥2 drugs from different pharmacological classes to reach their BP goals”
(Whelton et al, 2018)
Clinical Practice Guidelines
› Diabetes:– American College of Physicians “recommends that
clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered.”
(Qaseem, Barry, Humphrey & Forciea, 2017)
Clinical Practice Guidelines
› High Cholesterol:– Adults 40-75 years of age with an LDL-C 70-189 mg/dL without
clinical ASCVD or diabetes and an estimated ten-year ASCVD
risk ≥ 7.5% should be treated with moderate- to high-intensity statin therapy.
– Adults 40-75 years of age with diabetes mellitus and an LDL-C
70-189 mg/dL should be treated with moderate-intensity statin therapy.
– Individuals ≤ 75 years of age who have clinical ASCVD should
be treated with high-intensity statin therapy unless
contraindicated.
(Stone et al, 2014)
SOURCE: NCHS, Health, United States, 2016, Figure 16. Data from the National Health Interview Survey (NHIS)
Multiple PrescribersCase Study
› An 88-year-old female presents to your clinic with her daughter to discuss the arthritis pain in her hip. The patient has dementia which has been progressive. In reviewing her medications, what changes would you consider?
8/13/18
6
Medication List› Lisinopril 5mg once a day› Omega-3 fish oil 3 times a
day› Vitamin D 4,000 IU once a
day› Calcium 1500mg daily› Aspirin 81mg every other
day› Synthroid 137 mcg daily
› Aricept 10mg at bedtime› Probiotic Formula 1 tab
daily› Alfalfa tabs 500mg 2 tabs
three times a day› Multivitamin 1 tablet daily› Oxybutynin 5mg 1 tab twice
a day› Omeprazole 20mg daily
Prescribing Cascades
› Adverse drug reaction is thought to be a new problem
› New drug is prescribed for “new problem”– Example: › Patient started on NSAID for arthritis develops
hypertension› Patient taking anti-diabetic medication has dyspepsia› Patient taking pain medication has constipation
(Barclay, Frassetto, Robb, & Mandel, 2018)
Other Contributors› Cultural expectation that every patient-provider
interaction needs to end in a prescription› Doctor shopping (often for the same problem)› Patient not knowing what medications they are on› Incomplete medication list (especially with
supplements)› “Save” or borrow medications› Self-medicating
(Divine, n.d.; Holmes & Todd, 2017)
Deprescribing Strategies
Deprescribing
(Deprescribing.org, 2018)
Beers Criteria
› List of potentially inappropriate medication use in older
adults
› Updated in 2015 (and 2018)
– Drugs for which dose adjustment is required based on kidney
function
– Drug-drug interactions
– Drug-disease interactions
› List of alternative pharmaceutical and non-pharmaceutical
options
(Fick et al., 2015; Hanlon et al., 2015)
8/13/18
7
Pocket card reference available from American Geriatrics Society at: https://geriatricscareonline.org/ProductAbstract/beers-criteria-pocketcard/PC001
Deprescribing.org› Website with tools to help with deprescribing› Information on research initiatives› Deprescribing Guidelines and Algorithms› Patient decision aids› Webinars› Information pamphlets
Deprescribing.org› https://deprescribing.org/› Guidelines & algorithms to reduce meds› Decision aids & pamphlets
References
› Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project. (2018). Adverse drug events in U.S. hospitals, 2010 versus 2014 (Statistical Brief #234). Retrieved from https://www.hcup-us.ahrq.gov/reports/statbriefs/sb234-Adverse-Drug-Events.pdf
› Barclay, K., Frassetto, A., Robb, J., & Mandel, E. D. (2018). Polypharmacy in the elderly: How to reduce adverse drug events Frontline Medical Communications.
› Bouwmeester, C. & Devlin, J. W. (2019). Medication assessment in older adults. In T. Fulmer & B. Chernof (Eds.), Handbook of geriatric assessment (5th ed.) (pp. 305-312). Burlington, MA: Jones & Bartlett.
› Centers for Disease Control and Prevention, Medication Safety Program. (2018). Adverse drug events in adults. Retrieved from https://www.cdc.gov/medicationsafety/adult_adversedrugevents.html
› Djatche, L., Lee, S., Singer, D., Hegarty, S. E., Lombardi, M., & Maio, V. (2018). How confident are physicians in deprescribing for the elderly and what barriers prevent deprescribing? Journal of Clinical Pharmacy & Therapeutics, 43(4), 550-555. doi:10.1111/jcpt.12688
› Divine, H. (n.d). Safe medication use in the older adult. College of Pharmacy, Department of Pharmacy Practice & Science, University of Kentucky. Retrieved from file:///C:/Users/susan/Documents/TNP%20presentation/020-Divine.pdf
› Drenth-van Maanen, A. C., Leendertse, A. J., Jansen, P. A. F., Knol, W., Keijsers, C. J. P. W., Meulendijk, M. C., & van Marum, R. J. (2018). The systematic tool to reduce inappropriate prescribing (STRIP): Combining implicit and explicit prescribing tools toimprove appropriate prescribing. Journal of Evaluation in Clinical Practice, 24(2), 317-322. doi:10.1111/jep.12787
› Fick, D. M., Semla, T. P., Beizer, J., Brandt, N., Dombrowski, R., DuBeau, C. E., . . . Steinman, M. (2015). American geriatrics society 2015 updated beers criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 63(11), 2227-2246. doi:10.1111/jgs.13702
› Fletcher, K. (2014). Changes with aging. In Advanced practice nursing in the care of older adults (pp. 2-7). Philadelphia: F. A. Davis.
› Guharoy, R. (2017). Polypharmacy: America's other drug problem American Society of Health System Pharmacists. doi:10.2146/ajhp170404
References› Hanlon, J. T., Semla, T. P., & Schmader, K. E. (2015). Alternative medications for medications in the use of high-risk
medications in the elderly and potentially harmful drug-disease interactions in the elderly quality measures. Journal of the American Geriatrics Society, 63(12), e8-e18. doi:10.1111/jgs.13807
› Holmes, H. M. & Todd, A. (2017). The role of patient preferences in deprescribing. Clinics in Geriatric Medicine, 33, 165-175. doi: 10.1016/j.cger.2017.01.004
› Katzung, B. G. (2018). Special aspects of geriatric pharmacology. In B. G. Katzung (Ed.), Basic & clinical pharmacology (14th
ed.) (pp. 1058-1067). New York: McGraw-Hill.
› Masnoon, N., Shakib, S., Kalisch-Ellett, L., & Caughey, G. E. (2017). What is polypharmacy? A systematic review of definitions. BMC Geriatrics, 17, 230. http://doi.org/10.1186/s12877-017-0621-2
› Meulendijk, M., Spruit, M., Drenth-van Maanen, A., Numans, M., Brinkkemper, S., Jansen, P., & Knol, W. (2015). Computerized decision support improves medication review effectiveness: An experiment evaluating the STRIP assistant's usability. Drugs & Aging, 32(6), 495-503. doi:10.1007/s40266-015-0270-0
› National Council on Aging, NCOA Blog. (2017). Top 10 chronic conditions in adults 65+ and what you can do to prevent or manage them. Retrieved from https://www.ncoa.org/blog/10-common-chronic-diseases-prevention-tips/
› O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M. N., Ryan, C., & Gallagher, P. (2015). STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age & Ageing, 44(2), 213-218.
› Qaseem, A., Barry, M. J., Humphrey, L. L., & Forciea, M. A. (2017). Oral pharmacologic treatment of type 2 diabetes mellitus: A clinical practice guideline update from the American college of physicians, 166(4), 279-290. Doi: 10.7326/M16-1860
› Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V. B., & Alexander, G. C. (2016). Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Internal Medicine, 176(4), 473-482. doi: 10.1001/jamainternmed.2015.8581
› Rochon, P. A., & Gurwitz, J. H. (2017). The prescribing cascade revisited. Lancet, 389(10081), 1778-1780. doi:10.1016/S0140-6736(17)31188-1
› Scott, I. A., Hilmer, S. N., Reeve, E., Potter, K., LeCouteur, D., Rigby, D., . . .Martin, J. H. (2015). Reducing inappropriate polypharmacy: The process of deprescribing. JAMA Internal Medicine, 175(5), 827-834. doi: 10.1001/jamainternmed.2015.0324
› Steinman, M. A. & Holmes, H. M. (2014). Principles of prescribing for older adults. In B. A. Williams, A. Chang, C. Ahalt, H. Chen, R. Conant, C. Landefeld, C. Ritchie & M. Yukawa (Eds.), Current diagnosis & treatment: Geriatrics (2nd ed). New York, NY: McGraw-Hill.
› Stone, N. J., Robinson, J. G., Lichtenstein, A. H. Bairey, C. N., Blum, C. B. Eckel, R. H., Goldberg, A. C. . . .Wilson, P. W. (2014). 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/American heart association task force on practice guidelines. Circulation 129(Suppl. 2), S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a. Retrieved from https://www.ahajournals.org/doi/pdf/10.1161/01.cir.0000437738.63853.7a
› U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. (2017). Health, United States, 2016: With chartbook on Long-term trends in health (DHHS Publication No. 2017-1232). Retrieved from https://www.cdc.gov/nchs/data/hus/hus16.pdf#079
› U.S. Department of Health and Human Services, U.S. Food and Drug Administration. (2018). FDA adverse events reporting system (FAERS) public dashboard. Retrieved from https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/7a47a261-d58b-4203-a8aa-6d3021737452/state/analysis
› Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., . . . Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of Cardiology/American heart association task force on clinical practice guidelines doi:https://doi-org.ezp.twu.edu/10.1016/j.jacc.2017.11.006
› Zhou, L., & Rupa, A. P. (2018). Categorization and association analysis of risk factors for adverse drug events. European Journal of Clinical Pharmacology, 74(4), 389-404. doi:10.1007/s00228-017-2373